会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 83. 发明授权
    • Production of nanaomycin A and derivatives thereof
    • 生产纳诺霉素A及其衍生物
    • US4196266A
    • 1980-04-01
    • US858215
    • 1977-12-07
    • Satoshi OmuraHaruo TanakaJuichi AwayaToju Hata
    • Satoshi OmuraHaruo TanakaJuichi AwayaToju Hata
    • C12P17/06C12D9/14
    • C12R1/465C12P17/06Y10S435/886
    • The present invention relates to new compound nanaomycin A and derivatives thereof represented by general formula: ##STR1## in which (a) R is H and R' is OH (nanaomycin A),(b) R is H and R' is NH.sub.2 (nanaomycin C),(c) R is COCH.sub.3 and R' is CH (acetylnanaomycin A), and(d) R is H and R' is OCH.sub.3 (nanaomycin A methyl ester).Nanaomycin A is a new compound of quinone type and its acute toxicity (LD.sub.50, intra-penetrial injection) in mice is 28.2 mg/Kg. Nanaomycin A and derivatives thereof are active on Gram-positive bacteria, trichophyton and mycoplasma and are useful as a medicament for humans and animals. Nanaomycins A and C are produced by culturing a nanaomycin-producing strain belonging to the genus Streptomyces aerobically in a medium to accumulate nanaomycins A and C in the cultured broths. The derivatives acetylnanaomycin A and nanaomycin A methyl ester have similar properties to those of nanaomycin A.
    • 本发明涉及由以下通式表示的新化合物纳那霉素A及其衍生物:其中(a)R是H,R'是OH(纳那霉素A),(b)R是H和R' 是NH2(纳那霉素C),(c)R是COCH 3,R'是CH(乙酰氨基霉素A),和(d)R是H,R'是OCH 3(纳诺霉素A甲酯)。 Nanaomycin A是醌类的新化合物,其在小鼠中的急性毒性(LD50,内渗注射)为28.2mg / Kg。 纳诺霉素A及其衍生物对革兰氏阳性菌,毛毛虫和支原体具有活性,可用作人和动物的药物。 Nanaomycins A和C通过在培养基中培养产生链霉菌属的链霉菌属的纳米霉素生产菌株在培养基中培养以在培养的肉汤中积累纳米菌素A和C而产生。 乙酰纳他霉素A和纳那霉素A甲酯的衍生物具有与纳那霉素A相似的性质。
    • 84. 发明授权
    • Production of nanaomycin B
    • 生产纳诺霉素B
    • US4194064A
    • 1980-03-18
    • US858216
    • 1977-12-07
    • Satoshi OmuraHaruo TanakaJuichi AwayaToju Hata
    • Satoshi OmuraHaruo TanakaJuichi AwayaToju Hata
    • C12P17/06C12D9/14
    • C12R1/465C12P17/06Y10S435/886
    • The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/kg. Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.
    • 本发明涉及以通式表示的纳那霉素B的新化合物:< IMAGE> Nanaomycin B是醌类,对支原体,革兰氏阳性菌和真菌是有活性的。 该化合物可用作由毛癣菌或支原体寄生虫等引起的人类和动物感染性疾病的药物。该化合物小鼠的急性毒性(LD50,内渗注射)为169mg / kg。 纳豆霉素B通过发酵生产,其中在需氧条件下培养在属于链霉菌属的纳米霉素生产菌株,并从其中回收培养肉汤中积累的纳诺霉素B.
    • 88. 发明授权
    • Compound of stemphones and production thereof
    • 手机和其生产的组合
    • US07982057B2
    • 2011-07-19
    • US11911868
    • 2006-03-15
    • Satoshi OmuraHiroshi TomodaRokuro Masuda
    • Satoshi OmuraHiroshi TomodaRokuro Masuda
    • C07D311/78
    • C12P17/06C07D493/04
    • The present invention relates to novel compound of stemphones obtained by culturing microorganism belonging to genus Aspergillus and having ability to produce compound of stemphones selected from the group consisting of stemphone D substance, stemphone E substance, stemphone E1 substance, stemphone E2 substance, stemphone E3 substance and stemphone F substance, accumulating the compound of stemphones in the cultured mass, and isolating the compound of stemphones from the cultured mass. Since the obtained compound has enhancing activity for imipenem and activity for reducing cytotoxicity, it can be expected to be useful as lead compounds for combination remedy for methicillin resistant Staphylococcus aureus (MRSA) infection.
    • 本发明涉及通过培养属于曲霉属微生物的微生物获得的具有能够产生选自以下的干细胞的化合物的新型化合物:选自以下的组合:选自以下的组合:干扰素D物质,主体E物质, 和干扰素F物质,将培养物质中的电话的化合物积聚,并从培养的物质中分离出手机的化合物。 由于所得化合物对亚胺培南具有增强的活性和降低细胞毒性的活性,因此可预期作为用于耐甲氧西林金黄色葡萄球菌(MRSA)感染的组合治疗的铅化合物是有用的。